- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Aragen to Invest Rs 150 Crore to Expand CRDMO Capacity Ahead of IPO

Aragen expects to spend about Rs 100 crore on its contract development and manufacturing operations, while roughly Rs 40 crore will be invested in its discovery and contract research business, MD and CEO Manmahesh Kantipudi told Reuters in an interview last month.
The expansion comes as Aragen prepares for a stock market debut - comprising a fresh issue of Rs 802.7 crore and an offer for sale of up to 27.3 million shares - and seeks to increase capacity across small molecules and complex biologics, areas it sees as key drivers of future growth.
Aragen helps pharmaceutical companies with the discovery, development and manufacture of drugs. The firm plans to expand its small-molecule manufacturing capacity to 650 kilolitres from 364 kilolitres, while biologics manufacturing capacity is set to increase to 8.5 kilolitres by next year from 2.5 kilolitres.
The company, which has 591 customers, derives about 65% of revenue from drug discovery services and the rest from development and manufacturing operations.
"We are going to leverage our customers for that growth," Kantipudi said. "There's a lot of headroom to grow (in CDMO)."
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

